cis-u. trans-3-Ethoxycyclobutyl-bromid | 59138-94-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: cis-u. trans-3-Ethoxycyclobutyl-bromid
• 英文别名: 1-Bromo-3-ethoxycyclobutane
• CAS: 59138-94-2
• 化学式: C₆H₁₁BrO
• mdl: MFCD20631002
• 分子量: 179.057
• InChiKey: YVGAMOVMFISILV-UHFFFAOYSA-N

物化性质

• 沸点：
  171.7±33.0 °C(Predicted)
• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS<br/>[FR] COMPOSÉS DE PYRAZOLE ET PROCÉDÉ DE FABRICATION ET D'UTILISATION DE CES COMPOSÉS
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2016172560A1

  公开（公告）日：2016-10-27

  Disclosed embodiments of the formula below concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

  下面的公开实施例涉及新型白细胞介素受体相关激酶（IRAK）抑制剂和包含这种抑制剂的组合物。还公开了制备和使用这些化合物和组合物的方法。公开的化合物和/或组合物可用于治疗或预防与IRAK相关的疾病或症状。
• IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS
  申请人：BIOGEN MA INC.

  公开号：US20220089592A1

  公开（公告）日：2022-03-24

  This invention relates to Imidazo[1,2-a]pyridinyl Derivatives of formula (I′), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The invention further provides a method of manufacturing compounds of the invention, and methods for their therapeutic use. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including inflammatory disease, autoimmune disease, cancer, cardiovascular disease, a disease of the central nervous system, disease of the skin, an ophthalmic disease and condition, and a bone disease.

  这项发明涉及Imidazo[1,2-a]pyridinyl Derivatives的化合物（I′）或其药学上可接受的盐，其中所有变量如规范中所定义，能够调节IRAK4的活性。该发明进一步提供了一种制造该发明化合物的方法，以及它们在治疗中的方法。该发明还提供了它们的制备方法，医学用途，特别是在治疗和管理炎症性疾病、自身免疫疾病、癌症、心血管疾病、中枢神经系统疾病、皮肤疾病、眼科疾病和骨骼疾病等疾病或疾病的用途。
• Pyrazole compounds and method for making and using the compounds
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US10208075B2

  公开（公告）日：2019-02-19

  Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

  所公开的实施方案涉及新型白细胞介素受体相关激酶（IRAK）抑制剂和包含此类抑制剂的组合物。还公开了制造和使用这些化合物和组合物的方法。所公开的化合物和/或组合物可用于治疗或预防IRAK相关疾病或病症。
• Pyrazole compounds and methods for making and using the compounds
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US11370808B2

  公开（公告）日：2022-06-28

  Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

  所公开的实施方案涉及新型白细胞介素受体相关激酶（IRAK）抑制剂和包含此类抑制剂的组合物。还公开了制造和使用这些化合物和组合物的方法。所公开的化合物和/或组合物可用于治疗或预防IRAK相关疾病或病症。
• PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：EP3286181A1

  公开（公告）日：2018-02-28